Financial Performance - Revenue for Q3 2025 was $14.3 million, compared to $15.2 million in Q3 2024[7] - Like-for-like revenue (excluding discontinued product lines) was $14.2 million in Q3 2025, compared to $14.6 million in Q3 2024[4, 7] - Gross profit increased to $6.5 million in Q3 2025 from $5.3 million in Q3 2024, with gross margin improving to 45.2% from 35.0%[7] - The company achieved positive Adjusted EBITDA of $0.5 million for the quarter, compared to negative $1.4 million in Q3 2024[4] - Net loss was $5.1 million in Q3 2025, compared to $4.8 million in Q3 2024[4] - Basic and diluted loss per ADS was $0.28 in Q3 2025, compared to $0.46 in Q3 2024[4] Key Revenue Drivers - TrinScreen HIV sales were $1.0 million in Q3 2025, compared to $2.4 million in Q3 2024, reflecting the resumption of manufacture[7] - UniGold HIV sales showed strong performance with sales of $2.6 million in Q3 2025, compared to $1.6 million in Q3 2024[7] - Haemoglobin revenue increased to $5.7 million in Q3 2025 from $5.1 million in Q3 2024[7] Expenses and Liquidity - R&D expense was $0.8 million in Q3 2025, compared to $1.0 million in Q3 2024[10] - SG&A expense decreased to $6.2 million in Q3 2025 from $6.5 million in Q3 2024[10] - Cash balance at the end of Q3 2025 was $1.3 million, compared to $2.8 million in Q3 2024[10]

Core Insights - Trinity Biotech has received a significant order for 9 million units of its TrinScreen HIV screening product, indicating a recovery in the global HIV testing market [1][2][4] - The company achieved positive Adjusted EBITDA in Q3 2025 and anticipates further profitability growth in Q1 and Q2 2026 through its Comprehensive Transformation Plan [1][8][10] TrinScreen HIV Order - The order reflects renewed commitment from global health organizations to support HIV screening, particularly in heavily affected regions [2] - TrinScreen HIV is a WHO-prequalified rapid diagnostic test designed for high-volume screening, providing reliable results in various clinical settings [2] Manufacturing and Supply Chain - Trinity Biotech will produce the tests through a WHO-approved outsourced manufacturing process, allowing for efficient scalability [3] - The company expects to fulfill the order in Q4 2025 and Q1 2026, adjusting its manufacturing and supply chain to meet increased demand [3] Financial Performance - Revenues for Q3 2025 increased by 32% to $14.3 million compared to $10.8 million in Q2 2025, driven by a $2.1 million increase in rapid HIV test sales and a rise in haemoglobin product sales [8] - Gross profit for Q3 2025 was $6.5 million, with an increase in gross margin from 42.6% to 45.2% due to operational changes [8] - Adjusted EBITDA for Q3 2025 was $0.5 million, a significant improvement from negative $2.1 million in Q2 2025 [8] Strategic Positioning - The order is expected to positively impact revenue and profitability, highlighting the company's strategic position in the global infectious disease diagnostics market [4] - The company is focused on immediate growth opportunities and expanding into international markets with new product offerings [7][14] Management Transition - Susan O'Connor has completed her term as interim Chief Financial Officer, with Paul Murphy promoted to the role [10]

Core Insights - Trinity Biotech plc reported a total revenue of $15.9 million for Q4 2024, representing an 18.1% increase from $13.4 million in Q4 2023, driven primarily by a significant growth in Point-of-Care revenues [3][10] - The company is undergoing a Comprehensive Transformation Plan aimed at improving profitability, which includes consolidating manufacturing operations and enhancing offshore production capabilities [5][15] - Despite revenue growth, the company reported a net loss of $17.0 million for Q4 2024, an increase from $5.5 million in Q4 2023, largely due to restructuring costs and increased operational expenses [7][12] Financial Performance - Q4 2024 total revenues were $15.9 million, up from $13.4 million in Q4 2023, with Point-of-Care revenues increasing by 158.0% to $5.5 million [3][10] - Clinical laboratory revenues decreased by 8.6% to $10.3 million, attributed to a 34.3% decline in Infectious Diseases revenues [4][10] - For the fiscal year 2024, total revenues were $61.6 million, an 8.3% increase from $56.8 million in 2023, with Point-of-Care revenues growing by 91.8% [10][11] Profitability and Losses - Gross profit for Q4 2024 was $4.9 million, with a gross margin of 30.8%, down from 34.0% in Q4 2023 [6][10] - The net loss for the fiscal year 2024 was $31.8 million, compared to a loss of $24.0 million in 2023, influenced by restructuring costs and a decrease in impairment charges [12][13] - Selling, general, and administrative expenses decreased by $2.3 million to $28.8 million in 2024, reflecting cost-cutting measures [13] Cash Flow and Liquidity - The cash balance increased to $5.2 million at the end of Q4 2024 from $3.7 million at the end of Q4 2023, with cash generated from operating activities rising to $3.6 million [8][10] - The company entered into an amended credit agreement with Perceptive Advisors, providing an additional liquidity of approximately $4.5 million [15][16] Strategic Initiatives - The company has made significant progress in consolidating its manufacturing operations, including the transfer of production processes to other sites and the reduction of headcount at its Kansas facility [5] - Trinity Biotech is advancing the development of its next-generation continuous glucose monitoring (CGM) solution, with recent pre-pivotal testing completed [5][10]